市場調查報告書
商品編碼
1422960
2024-2032 年經導管肺動脈瓣市場(按技術、原料、應用、最終用戶和地區分類)Transcatheter Pulmonary Valve Market by Technology, Raw Material, Application, End User, and Region 2024-2032 |
2023年,全球經導管肺動脈瓣市場規模達到8,830萬美元。展望未來, IMARC Group預計到2032年市場規模將達到1.811億美元,2024-2032年複合年成長率(CAGR)為8.06%。各種心血管疾病(CVD)發生率的增加、廣泛的研發(R&D)活動以及老年人口的增加是推動市場發展的一些關鍵因素。
經導管肺動脈瓣是指由牛、豬或人類心臟組織製成的人工瓣膜。它被廣泛用於替換滲漏或狹窄的肺動脈瓣以改善血流,與開放性手術相比切口更少,恢復更快。這些瓣膜透過細而軟性的管子(導管)插入大血管,涉及微創 (MI) 手術。經導管肺動脈瓣置換術疼痛較少,恢復期較短,有助於改善症狀,同時降低醫療併發症的風險。它還有助於恢復血流並減少主動脈瓣狹窄的體徵和症狀,例如胸痛、氣短、昏厥和疲勞。因此,這些瓣膜在心臟異常、肺動脈瓣逆流、閉鎖、狹窄和動脈幹等方面有廣泛的應用。
全球風濕性心臟病、高血壓心臟病、腦血管疾病和發炎性心臟病等各種心血管疾病(CVD)發生率的上升是推動市場成長的關鍵因素之一。與此一致的是,老年人口的增加以及與嚴重主動脈瓣狹窄和二尖瓣和三尖瓣逆流相關的退化性異常盛行率的增加有利於市場的成長。此外,產品在兒科經導管肺治療中的廣泛採用也促進了市場的成長。這主要歸因於肺動脈狹窄、閉鎖、法洛氏四合症和其他相關疾病的發生頻率不斷增加,這促進了產品作為有效治療選擇的採用。除此之外,人工智慧(AI)在經導管肺動脈瓣置換術(TPVR)手術中的整合,因為它有助於術前規劃、識別風險因素以及加強診斷和臨床決策,從而推動了市場成長。此外,對球囊擴張技術的需求不斷成長,因為它涉及更快、更簡單的過程,並提供高精度的結果,這對市場成長產生了積極影響。除此之外,Hydra 主動脈瓣的推出正在推動市場成長,Hydra 主動脈瓣是一種由鎳鈦合金製成的自擴張超環形主動脈系統,可精確放置瓣膜並確保原位部署。其他因素包括對創新心臟瓣膜的需求不斷成長、高血壓病例數量不斷增加、醫療保健行業不斷成長、消費者支出能力不斷增強、廣泛的研發(R&D) 活動以及政府實施各種旨在開發高效心臟瓣膜的舉措經導管肺動脈瓣預計將為市場創造積極的前景。
The global transcatheter pulmonary valve market size reached US$ 88.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 181.1 Million by 2032, exhibiting a growth rate (CAGR) of 8.06% during 2024-2032. The increasing incidence of various cardiovascular diseases (CVDs), extensive research and development (R&D) activities, and the rising geriatric population represent some of the key factors driving the market.
A transcatheter pulmonary valve refers to an artificial valve made from cow, pig, or human heart tissue. It is widely used to replace leaky or narrowed pulmonary valves to improve blood flow, with fewer incisions and faster recovery than open surgery. These valves are inserted through a thin, flexible tube (catheter) into a large blood vessel involving a minimally invasive (MI) procedure. Transcatheter pulmonary valve replacement involves less pain and a shorter recovery period and helps in improving symptoms while lowering the risk of medical complications. It also helps to restore blood flow and reduce the signs and symptoms of aortic valve stenosis, such as chest pain, shortness of breath, fainting, and fatigue. As a result, these valves find extensive applications in cardiac anomaly, pulmonary regurgitation, atresia, stenosis, and truncus arteriosus.
The rising incidences of various cardiovascular diseases (CVDs), such as rheumatic heart disorders, hypertensive heart diseases, cerebrovascular diseases, and inflammatory heart diseases across the globe, are among the key factors driving the market growth. In line with this, the rising geriatric population and increasing prevalence of degenerative abnormalities associated with severe aortic stenosis and mitral and tricuspid regurgitation are favoring the market growth. Moreover, the widespread product adoption in the treatment of pediatric transcatheter pulmonary is contributing to the market growth. This can be primarily attributed to the increasing frequency of pulmonary stenosis, atresia, tetralogy of Fallot, and other related disorders, which is facilitating the product adoption as an effective treatment option. Apart from this, the integration of artificial intelligence (AI) in the transcatheter pulmonary valve replacement (TPVR) procedure, as it assists in pre-procedural planning, identifying risk factors, and enhancing diagnosis and clinical decision-making, is providing an impetus to the market growth. Additionally, the increasing demand for balloon-expanded technology as it involves a faster and simpler process and offers high accuracy and precision of the result is positively influencing the market growth. Besides this, the launch of the hydra aortic valve, which is a self-expanding supra-annular aortic system made of nitinol that allows precise placement of the valve and ensures orthotopic deployment, is propelling the market growth. Other factors, including growing demand for innovative heart valves, an increasing number of hypertension cases, escalating growth in the healthcare industry, rising expenditure capacities of consumers, extensive research and development (R&D) activities, and the implementation of various government initiatives to develop efficient transcatheter pulmonary valves, are anticipated to create a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each segment of the global transcatheter pulmonary valve market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on technology, raw material, application, and end user.
Balloon-Expanded Transcatheter Valve
Self-Expanded Transcatheter Valve
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the technology. This includes balloon-expanded transcatheter valve and self-expanded transcatheter valve. According to the report, balloon-expanded transcatheter valve represented the largest segment.
Tissue Engineered
Synthetic
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the raw material. This includes tissue engineered and synthetic. According to the report, tissue engineered represented the largest segment.
Tetralogy of Fallot
Cardiac Anomaly
Pulmonary Atresia
Pulmonary Stenosis
Pulmonary Regurgitation
Truncus Arteriosus
Others
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the application. This includes tetralogy of fallot, cardiac anomaly, pulmonary atresia, pulmonary stenosis, pulmonary regurgitation, truncus arteriosus, and others. According to the report, tetralogy of fallot represented the largest segment.
Adult
Pediatric
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the end user. This includes adult and pediatric. According to the report, adult represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others);Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for transcatheter pulmonary valve. Some of the factors driving the North America transcatheter pulmonary valve market included the rising geriatric population, growing demand for innovative heart valves, and various technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global transcatheter pulmonary valve market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Artivion Inc., Boston Scientific Corporation, Braile Biomedica, Colibri Heart Valve LLC, Edwards Lifesciences Corporation, JenaValve Technology Inc., Labcor Laboratorios Ltda., Medtronic plc, Venus Medtech (Hangzhou) Inc., etc.